[
  {
    "ts": null,
    "headline": "3 Monster Stocks in the Making",
    "summary": "Here's why they think biotech stocks CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) could become much larger.  David Jagielski (CRISPR Therapeutics): If you're looking for stocks with mammoth upside, you might be tempted to look for risky stocks that don't have any approved drugs or treatments yet.  In December 2023, regulators approved Casgevy, which is a gene-editing therapy the company has been developing with Vertex Pharmaceuticals.",
    "url": "https://finnhub.io/api/news?id=9e3ee739c8127729b4e5252155a3314ed7b9ab0357f47ba976a51815e3e0c255",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732361400,
      "headline": "3 Monster Stocks in the Making",
      "id": 131586506,
      "image": "https://g.foolcdn.com/editorial/images/798646/scientist-looking-through-microscope.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Here's why they think biotech stocks CRISPR Therapeutics (NASDAQ: CRSP), Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) could become much larger.  David Jagielski (CRISPR Therapeutics): If you're looking for stocks with mammoth upside, you might be tempted to look for risky stocks that don't have any approved drugs or treatments yet.  In December 2023, regulators approved Casgevy, which is a gene-editing therapy the company has been developing with Vertex Pharmaceuticals.",
      "url": "https://finnhub.io/api/news?id=9e3ee739c8127729b4e5252155a3314ed7b9ab0357f47ba976a51815e3e0c255"
    }
  }
]